Form 8-K 2seventy bio, Inc. For: Nov 12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Goldman Sachs Reiterates Sell Rating on 2Seventy Bio Inc. (TSVT)
November 12, 2024 12:52 PM ESTGoldman Sachs analyst Salveen Richter reiterated a Sell rating and $2.00 price target on 2Seventy Bio Inc. (NASDAQ: TSVT).
The analyst comments "TSVT reported 3Q US Abecma sales of $77mn (as reported by partner BMY) vs. GSe/Visible Alpha consensus of $70mn/$70mn, with Abecma profit-share of $11mn (vs. GSe/consesnus of $7mn/$11mn); GAAP EPS of ($0.19) was in line with consensus of ($0.19) (vs. GSe of ($0.34); Exhibit 1). While 3Q Abecma... More
